Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 1

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06206824Phase 1Recruiting

Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease

Role: collaborator

NCT05310552Completed

Elucidating Age-related Comorbidity Patterns in Down Syndrome (DS)

Role: collaborator

NCT03827525Unknown

Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome

Role: collaborator

NCT00394290Not ApplicableCompleted

Down Syndrome and Continuous Positive Pressure Therapy

Role: collaborator

NCT01041469Completed

Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome

Role: collaborator

NCT01034280Completed

Correlations Phenotype / Genotype in Down Syndrome

Role: collaborator

NCT00294593Phase 2Completed

Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome

Role: collaborator

All 7 trials loaded